Lymphoma & Plasma Cell Disorders
Conference Coverage
PET-driven chemo strategy helps reduce toxicity in Hodgkin lymphoma
CHICAGO – Results from the AHL2011 LYSA study show how PET findings can be used to de-escalate patients from BEACOPP to ABVD without losing out on...
News
Transplant strategy not viable for aggressive B-NHL
Transplant with radioimmunotherapy (RIT)-based conditioning is a viable treatment option for patients with indolent—but not aggressive—B-cell non-...
Conference Coverage
Rapid venetoclax dose escalation aids relapsed CLL
STOCKHOLM – A hospital-based dose-escalation protocol got CLL patients up to the target dose of venetoclax in 12 days, versus 35 days with the...
News
JAK inhibition linked to B-cell lymphoma
New research indicates that JAK inhibitors may increase the risk of lymphoma in patients with myelofibrosis (MF). The patients studied had a 15-...
Conference Coverage
Daratumumab plus carfilzomib/dexamethasone effective in lenalidomide-refractory myeloma
A triple-therapy regimen was well tolerated, with low rates of neutropenia both overall and in the lenalidomide-refractory subset of myeloma...
News
CHMP recommends CAR T for ALL, DLBCL
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of tisagenlecleucel (Kymriah®,...
News
CHMP recommends CAR T for DLBCL, PMBCL
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval for the chimeric antigen receptor (...
News
CHMP backs expanded approval of tocilizumab
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended expanding the approved use of tocilizumab (...
From the Journals
Bortezomib plus vorinostat shows modest response in MCL
The phase 2 trial looked at the combination in mantle cell lymphoma and diffuse large B-cell lymphoma patients.
Conference Coverage
Doc reports favorable results from trial on hold
STOCKHOLM—Interim trial results suggest the EZH2 inhibitor tazemetostat can produce durable responses in patients with relapsed or refractory...
News
Group updates guidelines on CLL
Recent advances in chronic lymphocytic leukemia (CLL) have prompted an update to the 2008 International Workshop in Chronic Lymphocytic Leukemia (...